Andrea Calcagno
Andrea Calcagno
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino
Email verificata su
Citata da
Citata da
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19
S Sciascia, F Aprà, A Baffa, S Baldovino, D Boaro, R Boero, S Bonora, ...
Clin Exp Rheumatol 38 (3), 529-532, 2020
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era
E Cerrato, F D'Ascenzo, G Biondi-Zoccai, A Calcagno, S Frea, ...
European heart journal 34 (19), 1432-1436, 2013
Cardiovascular disease in HIV patients: from bench to bedside and backwards
E Cerrato, A Calcagno, F D'ascenzo, G Biondi-Zoccai, M Mancone, ...
Open heart 2 (1), 2015
Ultrasensitive assessment of residual HIV viraemia in HAART‐treated patients with persistently undetectable plasma HIV‐RNA: A cross‐sectional evaluation
S Bonora, E Nicastri, A Calcagno, D Gonzalez de Requena, G D'Ettorre, ...
Journal of medical virology 81 (3), 400-405, 2009
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis
F D'Ascenzo, E Cerrato, A Calcagno, W Grossomarra, F Ballocca, ...
Atherosclerosis 240 (1), 197-204, 2015
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system
A Calcagno, G Di Perri, S Bonora
Clinical pharmacokinetics 53 (10), 891-906, 2014
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T> C polymorphism
M Siccardi, A D'Avolio, S Nozza, M Simiele, L Baietto, FR Stefani, D Moss, ...
Pharmacogenetics and genomics 20 (12), 759-765, 2010
Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control
A Calcagno, M Simiele, MC Alberione, M Bracchi, L Marinaro, S Ecclesia, ...
Clinical Infectious Diseases 60 (2), 311-317, 2015
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment
A D'Avolio, A Ciancio, M Siccardi, A Smedile, L Baietto, M Simiele, ...
Therapeutic drug monitoring 34 (2), 165-170, 2012
The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65–74 years and more than 75 years
G Guaraldi, A Malagoli, A Calcagno, C Mussi, BM Celesia, F Carli, ...
BMC geriatrics 18 (1), 99, 2018
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function
A Calcagno, DG de Requena, M Simiele, A D'Avolio, MC Tettoni, ...
Antimicrobial agents and chemotherapy 57 (4), 1840-1843, 2013
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms
A D'Avolio, C Carcieri, J Cusato, M Simiele, A Calcagno, S Allegra, ...
Journal of Antimicrobial Chemotherapy 69 (11), 3061-3066, 2014
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis
S Gili, W Grosso Marra, F D'Ascenzo, E Lonni, A Calcagno, M Cannillo, ...
European heart journal 37 (48), 3600-3609, 2016
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics
A Calcagno, A Yilmaz, J Cusato, M Simiele, R Bertucci, M Siccardi, ...
Aids 26 (12), 1529-1533, 2012
Unexpected drug–drug interaction between tipranavir/ritonavir and enfuvirtide
DG de Requena, A Calcagno, S Bonora, L Ladetto, A D'Avolio, ...
Aids 20 (15), 1977-1979, 2006
Impact of pre-therapy viral load on virological response to modern first-line HAART
MM Santoro, D Armenia, C Alteri, P Flandre, A Calcagno, C Gori, L Fabeni, ...
International Medical Press 18 (7), 867-876, 2013
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV‐positive patients using dried sample spot devices
A Calcagno, A D'Avolio, M Simiele, J Cusato, R Rostagno, V Libanore, ...
British journal of clinical pharmacology 74 (1), 134-140, 2012
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting
M Siccardi, A D'Avolio, S Rodriguez-Novoa, L Cuenca, M Simiele, ...
Therapeutic drug monitoring 34 (2), 232-235, 2012
Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment
A D'Avolio, A Ciancio, M Siccardi, A Smedile, M Simiele, J Cusato, ...
Therapeutic drug monitoring 34 (6), 722-728, 2012
HIV infection and primary prevention of cardiovascular disease: lights and shadows in the HAART era
F Ballocca, S Gili, F D’Ascenzo, WG Marra, M Cannillo, A Calcagno, ...
Progress in cardiovascular diseases 58 (5), 565-576, 2016
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20